Cortexyme plans path forward for Alzheimer's drug that failed study

Faced with the failure of a key clinical trial, a California-based biotech is pressing ahead with plans to test its experimental Alzheimer's drug in another study, convinced that signs of benefit observed in some patients are proof its treatment works.